Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1982 1
1984 1
1986 1
1989 1
1990 2
1994 1
1996 1
1999 1
2001 1
2002 1
2003 1
2004 1
2005 1
2006 1
2007 1
2008 1
2010 1
2011 4
2012 1
2013 3
2014 3
2015 1
2016 2
2017 3
2018 3
2019 2
2020 4
2021 4
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S. Tawbi HA, et al. Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Lancet Oncol. 2017. PMID: 28988646 Free PMC article. Clinical Trial.
Patients had histological evidence of metastatic or surgically unresectable locally advanced sarcoma, had received up to three previous lines of systemic anticancer therapy, had at least one measurable lesion according to the Response Evaluation Criteria In Solid Tu …
Patients had histological evidence of metastatic or surgically unresectable locally advanced sarcoma, had received up to three …
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.
Tang F, Tie Y, Wei YQ, Tu CQ, Wei XW. Tang F, et al. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188606. doi: 10.1016/j.bbcan.2021.188606. Epub 2021 Aug 8. Biochim Biophys Acta Rev Cancer. 2021. PMID: 34371128 Free article. Review.
Limited options with clinical efficacy for the metastatic or local advanced sarcoma existed despite standard therapy. Recently, targeted therapy according to the molecular and genetic phenotype of individual sarcoma is a promising option. ...
Limited options with clinical efficacy for the metastatic or local advanced sarcoma existed despite standard therapy. Recently …
Clinical markers of immunotherapy outcomes in advanced sarcoma.
Husain M, Quiroga D, Kim HG, Lenobel S, Xu M, Iwenofu H, Chen JL, Verschraegen C, Liebner D, Tinoco G. Husain M, et al. BMC Cancer. 2023 Apr 7;23(1):326. doi: 10.1186/s12885-023-10758-w. BMC Cancer. 2023. PMID: 37029351 Free PMC article.
In this study, we explore responses to ICI based on ICI regimen and other covariates to identify significant clinical factors in advanced sarcoma outcomes. METHODS: Patients in The Ohio State University Sarcoma Clinics were enrolled in the Sarcoma Retrospective ICI …
In this study, we explore responses to ICI based on ICI regimen and other covariates to identify significant clinical factors in advanced …
The Role of AKT in Soft Tissue Sarcoma: Review and Insights.
Wang Y, Ilyas FZ, Kheradmandi M, Tsilimigras DI, Grignol VP, Contreras C, Tsichlis PN, Pollock RE, Beane JD. Wang Y, et al. Mol Cancer Res. 2022 Oct 4;20(10):1471-1480. doi: 10.1158/1541-7786.MCR-21-0844. Mol Cancer Res. 2022. PMID: 35796636 Review.
In this review, we will first describe the AKT pathway and its role in STS tumor biology and then discuss the current challenges in targeting the AKT pathway to treat patients with advanced sarcoma....
In this review, we will first describe the AKT pathway and its role in STS tumor biology and then discuss the current challenges in targetin …
Advances of systemic treatment for adult soft-tissue sarcoma.
Liu W, Jiang Q, Zhou Y. Liu W, et al. Chin Clin Oncol. 2018 Aug;7(4):42. doi: 10.21037/cco.2018.08.02. Chin Clin Oncol. 2018. PMID: 30173532 Free article. Review.
There is more emerging evidence of different sensitivity to treatment for different histological subtypes, second-line treatment for advanced sarcoma is being increasingly driven by histology. Cytotoxic drugs such as dacarbazine, gemcitabine, and taxanes have shown …
There is more emerging evidence of different sensitivity to treatment for different histological subtypes, second-line treatment for adva …
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities.
Fendler WP, Pabst KM, Kessler L, Fragoso Costa P, Ferdinandus J, Weber M, Lippert M, Lueckerath K, Umutlu L, Kostbade K, Mavroeidi IA, Schuler M, Ahrens M, Rischpler C, Bauer S, Herrmann K, Siveke JT, Hamacher R. Fendler WP, et al. Clin Cancer Res. 2022 Oct 3;28(19):4346-4353. doi: 10.1158/1078-0432.CCR-22-1432. Clin Cancer Res. 2022. PMID: 35833949 Free PMC article.
PURPOSE: We report efficacy and safety of 90Y-labeled FAPI-46 (90Y-FAPI-46-RLT) in patients with advanced sarcoma, pancreatic cancer, and other cancer entities. EXPERIMENTAL DESIGN: Up to four cycles of radioligand therapy (RLT) were offered to patients with (i) pro …
PURPOSE: We report efficacy and safety of 90Y-labeled FAPI-46 (90Y-FAPI-46-RLT) in patients with advanced sarcoma, pancreatic …
Maintenance therapy and drug holiday in sarcoma patients: systematic review.
Lebellec L, Defachelles AS, Cren PY, Penel N. Lebellec L, et al. Acta Oncol. 2020 Sep;59(9):1084-1090. doi: 10.1080/0284186X.2020.1759825. Epub 2020 May 13. Acta Oncol. 2020. PMID: 32400254
Purpose: Overall prognosis of advanced sarcoma remains poor, optimization of systemic treatment is urgently needed in this setting.Materials and methods: We systematically reviewed fully published English-speaking literature about maintenance therapy and drug holida …
Purpose: Overall prognosis of advanced sarcoma remains poor, optimization of systemic treatment is urgently needed in this set …
Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients.
Weitao Y, Fangxing W, Qiqing C, Jiaqiang W. Weitao Y, et al. Anticancer Drugs. 2019 Aug;30(7):e0778. doi: 10.1097/CAD.0000000000000778. Anticancer Drugs. 2019. PMID: 31305297 Clinical Trial.
Sarcoma is a rare tumor with more than 50 histologic subtypes. Patients with advanced sarcoma have a poor prognosis. The aim of this study was to evaluate the efficacy and safety of apatinib, an oral vascular endothelial growth factor receptor-2 inhibitor, as salvag …
Sarcoma is a rare tumor with more than 50 histologic subtypes. Patients with advanced sarcoma have a poor prognosis. The aim o …
Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma.
Klemen ND, Hwang S, Bradic M, Rosenbaum E, Dickson MA, Gounder MM, Kelly CM, Keohan ML, Movva S, Thornton KA, Chi P, Nacev BA, Chan JE, Bartlett EK, Richards AL, Singer S, Donoghue MTA, Tap WD, D'Angelo SP. Klemen ND, et al. Clin Cancer Res. 2022 Mar 1;28(5):939-947. doi: 10.1158/1078-0432.CCR-21-3445. Clin Cancer Res. 2022. PMID: 34965948 Free PMC article.
Our primary endpoint was the incidence of HPD; secondary endpoints were clinical or genomic correlates of response or HPD. RESULTS: We treated 134 patients with advanced sarcoma from 2015 to 2019. Twenty-one patients (16%) had a complete or partial response (CR/PR), …
Our primary endpoint was the incidence of HPD; secondary endpoints were clinical or genomic correlates of response or HPD. RESULTS: We treat …
New targets for therapy of sarcoma.
Magenau JM, Schuetze SM. Magenau JM, et al. Curr Opin Oncol. 2008 Jul;20(4):400-6. doi: 10.1097/CCO.0b013e328303671d. Curr Opin Oncol. 2008. PMID: 18525335 Review.
PURPOSE OF REVIEW: Systemic treatment options for advanced sarcoma remain limited. Emerging trends exploring targeted therapy for the treatment of sarcoma are reviewed here. ...Agents targeting stem cell factor receptor (C-KIT), platelet-derived growth factor recept …
PURPOSE OF REVIEW: Systemic treatment options for advanced sarcoma remain limited. Emerging trends exploring targeted therapy …
54 results